[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015010240A2 - Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas - Google Patents

Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas

Info

Publication number
BR112015010240A2
BR112015010240A2 BR112015010240A BR112015010240A BR112015010240A2 BR 112015010240 A2 BR112015010240 A2 BR 112015010240A2 BR 112015010240 A BR112015010240 A BR 112015010240A BR 112015010240 A BR112015010240 A BR 112015010240A BR 112015010240 A2 BR112015010240 A2 BR 112015010240A2
Authority
BR
Brazil
Prior art keywords
pcrv
binding molecules
combination therapies
pseudomonal
psl
Prior art date
Application number
BR112015010240A
Other languages
English (en)
Inventor
Digiandomenico Antonio
Warrener Paul
Stover Charles
Sellman Bret
Minter Ralph
Guillard Sandrine
Rust Steven
Tomich Mladen
Venkatraman Vignesh
Varkey Reena
Peng Li
Damschroder Melissa
Chowdhury Partha
Dimasi Nazzareno
Fleming Ryan
Bezabeh Binyam
Gao Changshou
Original Assignee
Medimmune Ltd
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Medimmune Llc filed Critical Medimmune Ltd
Publication of BR112015010240A2 publication Critical patent/BR112015010240A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

TERAPIAS DE COMBINAÇÃO ATRAVÉS DO USO DE MOLÉCULAS DE LIGAÇÃO DE PSL E DE PCRV ANTI-PSEUDOMONAS. A presente invenção refere-se a terapias de combinação que compreendem moléculas de ligação de Ps1 e PcrV anti-Pseudomonas e composições relacionadas para o uso na prevenção e no tratamento de infecção por Pseudomonas
BR112015010240A 2012-11-06 2013-11-06 Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas BR112015010240A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723192P 2012-11-06 2012-11-06
PCT/US2013/068609 WO2014074528A2 (en) 2012-11-06 2013-11-06 Combination therapies using anti-pseudomonas psl and pcrv binding molecules

Publications (1)

Publication Number Publication Date
BR112015010240A2 true BR112015010240A2 (pt) 2017-08-22

Family

ID=50685302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010240A BR112015010240A2 (pt) 2012-11-06 2013-11-06 Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas

Country Status (11)

Country Link
US (1) US20150284450A1 (pt)
EP (1) EP2917236A2 (pt)
JP (1) JP2015535005A (pt)
KR (1) KR20150082367A (pt)
CN (1) CN104995209A (pt)
AU (1) AU2013341349A1 (pt)
BR (1) BR112015010240A2 (pt)
CA (1) CA2888211A1 (pt)
MX (1) MX2015005719A (pt)
SG (1) SG11201502937PA (pt)
WO (1) WO2014074528A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3385280A1 (en) 2011-06-10 2018-10-10 MedImmune Limited Anti-pseudomonas psl binding molecules and uses thereof
US10597439B2 (en) * 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
BR112017023378A2 (pt) * 2015-05-01 2018-07-24 Inhibrx Lp moléculas de direcionamento do sistema de secreção do tipo iii
MX2018000523A (es) 2015-07-16 2018-04-13 Inhibrx Lp Proteinas de fusion de union a dr5 multivalentes y multiespecificas.
CA3005665A1 (en) * 2015-11-30 2017-06-08 Medimmune Limited Method for preventing or treating nosocomial pneumonia
US20190153076A1 (en) * 2016-05-05 2019-05-23 The Trustees Of The University Of Pennsylvania DNA Antibody Constructs for Use against Pseudomonas Aeuruginosa
AU2018345312A1 (en) * 2017-10-02 2020-05-07 Aridis Pharmaceuticals, Inc. Compositions and methods against P. aeruginosa infections
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2021015156A (es) * 2019-06-11 2022-01-18 Regeneron Pharma Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
AU2020311511B2 (en) * 2019-07-09 2024-08-29 Beijing Solobio Genetechnology Co., Ltd. Antibodies specifically recognizing Pseudomonas PcrV and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof
EP4192856A4 (en) * 2020-08-07 2024-10-09 Beijing Solobio Genetechnology Co Ltd ANTIBODIES THAT SPECIFICALLY RECOGNIZE PSEUDOMONAS PSL AND THEIR USES
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
JP2023549911A (ja) * 2020-11-18 2023-11-29 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 シュードモナス属ｐｃｒｖおよびｐｓｌを特異的に認識する抗原結合を含む抗体の組み合わせ及び二重特異性抗体
TW202417478A (zh) 2022-06-29 2024-05-01 瑞典商阿斯特捷利康公司 用於治療支氣管擴張的抗PcrV和Psl雙特異性藥物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199802692T2 (xx) * 1996-06-24 1999-03-22 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Rhesus D antijenleri i�in spesifikli�i olan ba�lay�c� yap�lar olu�turabilen polipeptitler, bunlar� kodlayan DNA ve haz�rlanmalar� i�in i�lem ve kullan�mlar�
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
KR100918746B1 (ko) * 2004-09-06 2009-09-24 교와 핫꼬 기린 가부시키가이샤 항 ａ３３ 항체
AR051528A1 (es) * 2004-12-15 2007-01-17 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
KR20100097719A (ko) * 2007-11-30 2010-09-03 칼로바이오스 파마슈티컬스, 아이엔씨. 슈도모나스 아에루기노사의 ＰｃｒＶ 항원에 대한 항체
WO2009131239A1 (ja) * 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
EP2673373B3 (en) * 2011-02-08 2021-06-02 MedImmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
EP3385280A1 (en) * 2011-06-10 2018-10-10 MedImmune Limited Anti-pseudomonas psl binding molecules and uses thereof
US10597439B2 (en) * 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

Also Published As

Publication number Publication date
EP2917236A2 (en) 2015-09-16
SG11201502937PA (en) 2015-06-29
US20150284450A1 (en) 2015-10-08
WO2014074528A3 (en) 2014-07-03
CA2888211A1 (en) 2014-05-15
MX2015005719A (es) 2016-01-12
JP2015535005A (ja) 2015-12-07
AU2013341349A8 (en) 2015-12-03
CN104995209A (zh) 2015-10-21
WO2014074528A8 (en) 2015-05-21
AU2013341349A1 (en) 2015-05-21
WO2014074528A2 (en) 2014-05-15
KR20150082367A (ko) 2015-07-15

Similar Documents

Publication Publication Date Title
BR112015010240A2 (pt) Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO6852095A2 (es) Composiciones pesticidas y procedimientos relacionados con estas
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
CL2013003638A1 (es) Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas.
NI201400046A (es) AGENTES iARN, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
BR112014033116A2 (pt) anticorpos para tau
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
CO6741157A2 (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112013028908A2 (pt) anticorpos c-kit e usos dos mesmos
AR087715A1 (es) Anticuerpos anti pcsk9 y usos de los mismos
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112013029773A2 (pt) canabinoides para uso no tratamento de dor neuropática
BR112014009866A2 (pt) formulações de anticorpos e métodos
BR112014027995A2 (pt) uso de seaprose para remover biopelícula bacteriana
CR20140594A (es) Composiciones farmacéuticas y tratamiento de mastitis
IN2014CN04014A (pt)
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]